AngioDynamics, Inc. (ANGO)

NASDAQ: ANGO · IEX Real-Time Price · USD
24.26
-0.04 (-0.16%)
Aug 12, 2022 11:58 AM EDT - Market open
-0.16%
Market Cap 945.41M
Revenue (ttm) 316.22M
Net Income (ttm) -26.55M
Shares Out 38.97M
EPS (ttm) -1.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 29,265
Open 24.48
Previous Close 24.30
Day's Range 24.08 - 24.48
52-Week Range 17.56 - 32.00
Beta 0.90
Analysts Buy
Price Target 31.62 (+30.3%)
Earnings Date Sep 28, 2022

About ANGO

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date May 27, 2004
CEO James Clemmer
Employees 760
Stock Exchange NASDAQ
Ticker Symbol ANGO
Full Company Profile

Financial Performance

In 2022, AngioDynamics's revenue was $316.22 million, an increase of 8.66% compared to the previous year's $291.01 million. Losses were -$26.55 million, -15.85% less than in 2021.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ANGO stock is "Buy." The 12-month stock price forecast is 31.62, which is an increase of 30.34% from the latest price.

Price Target
$31.62
(30.34% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Is AngioDynamics (ANGO) Up 15.4% Since Last Earnings Report?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

AngioDynamics to Present at the Canaccord Genuity Growth Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expandin...

Should You Buy This Under-the-Radar Growth Stock?

Like the Nasdaq Composite, this little-known medical device stock has been beaten down in 2022.

Raymond James Cuts Price Target On AngioDynamics

Raymond James lowered the price target on AngioDynamics Inc (NASDAQ: ANGO) to $27 from $32 based on a 3.0x group multiple applied to the C23 revenue estimate. At 2.2x EV/sales, Raymond James believes AN...

AngioDynamics (ANGO) Q4 Earnings in Line, Revenues Beat Mark

AngioDynamics (ANGO) registers strong revenue growth in Med Tech and Med Device businesses, as well as in its GBUs, in fourth-quarter fiscal 2022.

AngioDynamics (ANGO) Q4 Earnings Match Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 0% and 5.27%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics Reports Fiscal Year 2022 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2023 Guidance

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expandin...

Here's Why You Should Retain AngioDynamics (ANGO) Stock Now

AngioDynamics (ANGO) continues to benefit from strength in segments, but forex remains a woe.

AngioDynamics to Report Fiscal 2022 Fourth Quarter and Full-Year Financial Results on July 12, 2022

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expandin...

AngioDynamics to Present at the UBS Global Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expandin...

AngioDynamics to Present at the BofA Securities Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expandin...

3 Reasons to Consider Buying This Overlooked Medical Device Stock

The Nasdaq's sell-off looks to have given investors a buying opportunity in this little-known medical device stock.

AngioDynamics (ANGO) Q3 Earnings Top Estimates, Revenues Lag

AngioDynamics (ANGO) registers strong revenue growth in its Med Tech business as well as domestic revenues in third-quarter fiscal 2022.

Why AngioDynamics Stock Soared 10% Today

AngioDynamics "beat earnings" in Q3 -- but what does that really mean?

AngioDynamics Posts Wider Q3 Loss On Higher Costs, Reaffirms FY22 Outlook

AngioDynamics Inc (NASDAQ: ANGO) has reported a Q3 FY22 adjusted EPS of $0.03, ahead of the consensus of $(0.01), and better than the consensus of $0.02 reported a year ago. Q3 sales increased 3.9% Y/Y ...

AngioDynamics Reports Fiscal 2022 Third Quarter Financial Results; Reaffirms Fiscal Year 2022 Guidance

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expandin...

AngioDynamics to Present at the Needham Virtual Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system and impro...

AngioDynamics to Report Fiscal 2022 Third Quarter Financial Results on April 7, 2022

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

AngioDynamics to Present at Three Investor Conferences in March

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

New Strong Sell Stocks for March 8th

ANGO, BURL, and CABGY have been added to the Zacks Rank #5 (Strong Sell) List on March 8, 2022.

Other symbols: BURL

AngioDynamics to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

Is This Small-Cap Medical Devices Stock a Buy?

AngioDynamics managed to deliver solid revenue growth in the second quarter despite COVID-19 headwinds.

AngioDynamics (ANGO) Q2 Earnings Lag Estimates, Revenues Top

AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs, as well as in domestic and international revenues in fiscal 2022 Q2.

AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

AngioDynamics to Present at the Needham Virtual Growth Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...